Robert Mamoun will be speaking at EU-Japan Biotech & Pharma Conference (Oct. 6~7). The pitch will be slot in the luncheon session on 6th (Monday) October from 12:10 - 13:20 at Hotel Hankyu International 4th floor. Focussing on Adiponectine and a breakthrough application on metabolic diseases, so make sure you…
‘DIADEME’ project awarded €6.5 million in government funding via France 2030, enabling Ciloa to advance the development of its bio-drug APN-sEV (Adiponectin associated with exosomes), the world's only recombinant, stable and functional form of Adiponectin First preclinical results confirm remarkable therapeutic potential in treatment of several metabolic diseases, in particular type…
Ciloa is proud to be part of the French Delegation at BIOUS 2025 Let’s connect and share about our sEV bioengineering platform EVENGI and in progress applications of our lead candidate, APN-sEV. Learn more about our breakthrough solution for obesity, diabetes, MASH and metabolic diseases based on adiponectin, a hormone…